Lilly ’s Rheumatoid Arthritis Drug Shortens Covid-19 Hospitalization When Combined With Antiviral Med
The pharmaceutical company said its drug baricitinib, combined with remdesivir, reduces median hospital stays by one day compared to remdesivir alone, and is pursuing an emergency use authorization with the FDA.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Coronavirus technology alexknappblog Source Type: news
More News: Arthritis | Coronavirus | COVID-19 | Emergency Medicine | Hospitals | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology | Science